Table 2.
Treatment and clinical outcomes of 1351 patients hospitalised with COVID-19.
| Patients without BSI N = 1282 (94.9%) |
Patients with CA/HCA-BSI N = 18 (1.3%) |
Patients with HA-BSI N = 51 (3.8%) |
p Value | Overall N = 1351 |
|
|---|---|---|---|---|---|
| COVID-19 treatment, N (%) | |||||
| lopinavir/r or darunavir/c | 130 (10.1%) | 0 (0.0%) | 7 (13.7%) | 0.253 | 137 (10.1%) |
| remdesivir | 136 (10.6%) | 2 (11.1%) | 6 (11.8%) | 0.964 | 144 (10.7%) |
| hydroxychloroquine +/− azithromycin | 414 (32.3%) | 5 (27.8%) | 20 (39.2%) | 0.534 | 439 (32.5%) |
| heparin prophylaxis | 874 (68.2%) | 10 (55.6%) | 41 (80.4%) | 0.091 | 925 (68.5%) |
| corticosteroids | 584 (45.6%) | 6 (33.3%) | 33 (64.7%) | 0.015 | 623 (46.1%) |
| immunomodulators | 57 (4.5%) | 0 (0.0%) | 3 (5.9%) | 0.581 | 60 (4.4%) |
| Highest grade of O2 therapy, N (%) | <0.001 | ||||
| IMV | 83 (6.5%) | 0 (0.0%) | 11 (21.6%) | 94 (7.0%) | |
| NIMV | 73 (5.7%) | 1 (5.6%) | 10 (19.6%) | 84 (6.2%) | |
| CPAP | 360 (28.1%) | 1 (5.6%) | 14 (27.5%) | 375 (27.8%) | |
| O2 low/high flow | 541 (42.2%) | 12 (66.7%) | 14 (27.5%) | 567 (42.0%) | |
| No O2 therapy | 225 (17.6%) | 4 (22.2%) | 2 (3.9%) | 231 (17.1%) | |
| Length of hospital stay, Median days (IQR) | 9 (5–17) | 12.5 (7–29) | 27 (21–35) | <0.001 | 10 (5–18) |
| ICU admission, N (%) | 90 (7.0%) | 0 (0.0%) | 11 (21.6%) | <0.001 | 101 (7.5%) |
| Death, N (%) | 319 (24.9%) | 6 (33.3%) | 16 (31.4%) | 0.421 | 341 (25.2%) |
CA/HCA-BSI = community-acquired/healthcare-associated bloodstream infection; HA-BSI = hospital-acquired bloodstream infection; IMV = Invasive Mechanical Ventilation; NIMV = Non-Invasive Mechanical ventilation; CPAP = Continuous positive airway pressure therapy; ICU = Intensive Care Unit.